[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364136-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364136-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","high-endothelial-venules-in-small-cell-lung-cancer-prognostic-subtypes-and-therapeutic-implications-for-immunoradiotherapy","High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy","","Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by an immunosuppressive tumor microenvironment, limiting the effectiveness of immunotherapy. High endothelial venules (HEVs) support lymphocyte recruitment and antitumor immunity, but their impact in SCLC is unclear. Integrated analyses of five bulk RNA-seq datasets (583 tumors) defined two HEV-related subtypes, C1 and C2, and C1 showed a more immune-active microenvironment and better prognosis. Single-cell RNA-seq and immunofluorescence validation in 80 patients confirmed HEV structures predict favorable outcomes. A prognostic model and nomogram were built, highlighting PDCD1, CXCL9, ITK, ITGAL, and SH2D1A as key favorable genes. In murine SCLC models, radiotherapy plus immunotherapy promoted HEV formation and increased antitumor efficacy, suggesting HEV-targeted combination strategies may overcome restricted immunotherapy benefits.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/high-endothelial-venules-in-small-cell-lung-cancer-prognostic-subtypes-and-therapeutic-implications-for-immunoradiotherapy/364136/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/high-endothelial-venules-in-small-cell-lung-cancer-prognostic-subtypes-and-therapeutic-implications-for-immunoradiotherapy/364136.png","ImageObject",300,407,{"name":42,"@type":43},"CatatanPagi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are HEVs and why are they relevant to small cell lung cancer?","Question",{"text":63,"@type":64},"HEVs are specialized vascular structures that facilitate lymphocyte recruitment and support antitumor immunity. The study focuses on their role in SCLC, where the immunosuppressive microenvironment limits immunotherapy benefit.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were HEV-related patient subtypes defined in the study?",{"text":68,"@type":64},"Five bulk RNA-seq datasets were integrated and HEV-related signatures stratified SCLC patients into two subtypes, C1 and C2, linked to HEV-high and HEV-low states.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic effect was observed when combining radiotherapy with immunotherapy in animal models?",{"text":72,"@type":64},"In murine SCLC models, radiotherapy combined with immunotherapy promoted HEV formation and enhanced antitumor efficacy, supporting HEVs as a key mediator of treatment synergy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364136,1790197190,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","International Journal of Cancer  \nRESEARCH ARTICLE  OPEN ACCESS   \nCancer Therapy and Prevention  \nHigh Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy  \nJiatian Fang1,2  | Zilian Wang2 | Hui Wang1,3 | Jianxin Xue1,3 | Kai Kang1,3  \n1Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China | 2West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China | 3Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, China  \nCorrespondence: Jianxin Xue ([xuejx@scu.edu.cn](xuejx@scu.edu.cn)) | Kai Kang ([kaikang@wchscu.edu.cn](kaikang@wchscu.edu.cn))  \nReceived: 23 March 2026 | Revised: 20 June 2026 | Accepted: 24 June 2026  \nKeywords: high endothelial venules | immunotherapy | radiotherapy | small cell lung cancer  \nABSTRACT  \nSmall cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy with an immunosuppressive tumor microenvironment, and current immunotherapy provides limited benefit. This highlights the need to identify microenvironmental features enabling effective immune responses. High endothelial venules (HEVs) are critical for lymphocyte recruitment and antitumor immunity, yet their roles in SCLC remain poorly understood. To investigate HEV-related features among SCLC patients, five bulk RNA-seq datasets comprising 583 tumor samples were integrated. HEV-related signatures stratified SCLC patients into two subtypes, C1 and C2, associated with HEV-high and HEV-low states, respectively. C1 showed a more immune-active microenvironment and superior prognosis. Consistently, using single-cell RNA-seq data and validating the findings by immunofluorescence staining in an independent cohort of 80 patients with SCLC, we confirmed that the presence of HEV structures was associated with a favorable prognosis. We further established a prognostic model and identified five genes, PDCD1, CXCL9, ITK, ITGAL, and SH2D1A, as key favorable prognostic factors. A nomogram incorporating age, tumor stage, and the prognostic model was also developed and exhibited satisfactory performance. Additionally, we explored the translational potential of promoting HEV formation as a therapeutic strategy in SCLC. In murine SCLC models, radiotherapy combined with immunotherapy promoted HEV formation and enhanced antitumor efficacy. HEVs appeared to serve as a critical link underlying the therapeutic synergy between radiotherapy and immunotherapy. Collectively, these findings highlight the biological and clinical relevance of HEVs in SCLC and suggest that combination strategies aimed at promoting HEV formation may help overcome the limited efficacy of immunotherapy.  \n\n| Abbreviations: ANOVA, analysis of variance; ASCL1, achaete-scute homolog 1; CCL19, C-C motif chemokine ligand 19; CCL21, C-C motif chemokine ligand 21; CIDE, Cancer Immunology Data Engine; C-index, Harrell's concordance index; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCL9, C-X-C motif chemokine ligand 9; DAPI, 4′,6-Diamidino-2-phenylindole; DCA, decision curve analysis; DEG, differentially expressed gene; EC, endothelial cell; ES, extensive-stage; FDR, false discovery rate; FFPE, formalin-fixed paraffin-embedded; GBM, Gradient Boosting Machine; GEO, Gene Expression Omnibus; GO, Gene Ontology; GSEA, gene set enrichment analysis; GSVA, gene set variation analysis; HEV, high endothelial venules; HRP, horseradish peroxidase; HTAN, Human Tumor Atlas Network; ICAM1, intercellular adhesion molecule 1; ICB, immune checkpoint blockade; K-M, Kaplan–Meier; LASSO, Least Absolute Shrinkage and Selection Operator; LS, limitedstage; MAST, Model-based Analysis of Single-cell Transcriptomic; ML, machine learning; MSigDB, molecular signature database; NE, neuroendocrine; NEUROD1, neuronal differentiation 1; NGDC, National Genomics Data Center; NK, natural killer; NMF, non-negative matrix factori","cbCaipUAdfX0X5Mz","https://ap.wps.com/l/cbCaipUAdfX0X5Mz","pdf",4421181,14,"English","# Introduction\n# Materials and Methods\n# Results\n## HEV-related signatures and SCLC subtypes\n## Validation and prognostic model\n## Therapeutic implications for immunoradiotherapy\n# Discussion","[{\"question\":\"What are HEVs and why are they relevant to small cell lung cancer?\",\"answer\":\"HEVs are specialized vascular structures that facilitate lymphocyte recruitment and support antitumor immunity. The study focuses on their role in SCLC, where the immunosuppressive microenvironment limits immunotherapy benefit.\"},{\"question\":\"How were HEV-related patient subtypes defined in the study?\",\"answer\":\"Five bulk RNA-seq datasets were integrated and HEV-related signatures stratified SCLC patients into two subtypes, C1 and C2, linked to HEV-high and HEV-low states.\"},{\"question\":\"What therapeutic effect was observed when combining radiotherapy with immunotherapy in animal models?\",\"answer\":\"In murine SCLC models, radiotherapy combined with immunotherapy promoted HEV formation and enhanced antitumor efficacy, supporting HEVs as a key mediator of treatment synergy.\"}]","High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy | PDF",1790155910,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46effab68d035202f3a6507a7691dace.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/846bcbe922ff29c82310b9665e978845.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bf0499e8bb2b91f35ea7c4bce4e5598.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99c41b6cd378b1f217c811d07aaba55d.webp",980,1287]